Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells

Journal of Controlled Release

Volumn 106, Issue 1-2, 2005, Pages 123-137

  Heisler, Iring ^a   Sutherland, Mark ^a   Bachran, Christopher ^a   Hebestreit, Philipp ^b   Schnitger, Anna ^a   Melzig, Matthias F ^b   Fuchs, Hendrik ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Cancer therapy; Epidermal growth factor; Immunotoxin; Recombinant chimeric toxin; Saponin; Saporin

Indexed keywords

CELLS; CONCENTRATION (PROCESS); CONTROLLED DRUG DELIVERY; GROWTH KINETICS; TOXICITY; TUMORS;

CANCER THERAPY; CHIMERIC TOXINS; CYTOTOXICITY; DOSES; IMMUNOTOXIN; RECOMBINANT TIMERIC TOXINS; SADPORIN; SYNERGISTIC TOXICITY;

TOXIC MATERIALS;

EPIDERMAL GROWTH FACTOR; IMMUNOTOXIN; POLYPEPTIDE; SAPONIN; SAPORIN; SAPORIN 3; TYROSYLVALYLHISTIDYLASPARTYLGLUTAMYLVALYLASPARTYLARGINYLPROLYLGLYCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CHIMERA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; EMBRYO; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL;

ANIMALS; CARYOPHYLLACEAE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; IMMUNOTOXINS; MICE; NIH 3T3 CELLS; PLANT PROTEINS; SAPONINS;

EID: 23744432460     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.04.006     Document Type: Article

References (34)

1. U. Brinkmann Recombinant antibody fragments and immunotoxin fusions for cancer therapy In Vivo 14 1 2000 21 27
2. C.F. LeMaistre, M.N. Saleh, T.M. Kuzel, F. Foss, L.C. Platanias, G. Schwartz, M. Ratain, A. Rook, C.O. Freytes, F. Craig, J. Reuben, and J.C. Nichols Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2 Blood 91 2 1998 399 405
3. P. Piascik FDA approves fusion protein for treatment of lymphoma J. Am. Pharm. Assoc. (Wash.) 39 4 1999 571 572
4. G.A. Wiseman, C.A. White, R.B. Sparks, W.D. Erwin, D.A. Podoloff, D. Lamonica, N.L. Bartlett, J.A. Parker, W.L. Dunn, S.M. Spies, R. Belanger, T.E. Witzig, and B.R. Leigh Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma Crit. Rev. Oncol./Hematol. 39 1-2 2001 181 194
5. G.A. Wiseman, C.A. White, M. Stabin, W.L. Dunn, W. Erwin, M. Dahlbom, A. Raubitschek, K. Karvelis, T. Schultheiss, T.E. Witzig, R. Belanger, S. Spies, D.H. Silverman, J.R. Berlfein, E. Ding, and A.J. Grillo-Lopez Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma Eur. J. Nucl. Med. 27 7 2000 766 777
6. P.R. Hamann, L.M. Hinman, I. Hollander, C.F. Beyer, D. Lindh, R. Holcomb, W. Hallett, H.R. Tsou, J. Upeslacis, D. Shochat, A. Mountain, D.A. Flowers, and I. Bernstein Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia Bioconjug. Chem. 13 1 2002 47 58
7. E.S. Vitetta Immunotoxins and vascular leak syndrome Cancer J. Sci. Am. 6 Suppl. 3 2000 S218 S224
8. J. Keller, I. Heisler, R. Tauber, and H. Fuchs Development of a novel molecular adapter for the optimization of immunotoxins J. Control Release 74 1-3 2001 259 261
9. I. Heisler, J. Keller, R. Tauber, M. Sutherland, and H. Fuchs A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins Int. J. Cancer 103 2 2003 277 282
10. P.M. Fischer, E. Krausz, and D.P. Lane Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation Bioconjug. Chem. 12 6 2001 825 841
11. A.M. Beerens, A.F. Al Hadithy, M.G. Rots, and H.J. Haisma Protein transduction domains and their utility in gene therapy Curr. Gene. Ther. 3 5 2003 486 494
12. A. Sjölander, and J.C. Cox Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines Adv. Drug Deliv. Rev. 34 2-3 1998 321 338
13. G. Ramon Procedes pour accroitre la production des antitoxines Ann. Inst. Pasteur Paris 40 1926 1 10
14. R.G. Espinet Nuevo tipo de vacuna antiaftosa a complejo glucovirico Gac. Vet. 13 1951 265 276
15. J.R. Alvarez, and R. Torres-Pinedo Interactions of soybean lectin, soyasaponins, and glycinin with rabbit jejunal mucosa in vitro Pediatr. Res. 16 9 1982 728 731
16. B. Morein, B. Sundquist, S. Hoglund, K. Dalsgaard, and A. Osterhaus Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses Nature 308 5958 1984 457 460
17. P. Hebestreit, and M.F. Melzig Cytotoxic activity of the seeds from Agrostemma githago var. githago Planta Med. 69 10 2003 921 925
18. S. Oess, and E. Hildt Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens Gene Ther. 7 9 2000 750 758
19. I. Heisler, J. Keller, R. Tauber, M. Sutherland, and H. Fuchs Colorimetric assay for the quantitation of free adenine applied to determine the enzymatic activity of ribosome-inactivating proteins Anal. Biochem. 302 1 2002 114 122
20. A.M. Honegger, T.J. Dull, S. Felder, E. Van Obberghen, F. Bellot, D. Szapary, A. Schmidt, A. Ullrich, and J. Schlessinger Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing Cell 51 2 1987 199 209
21. P. Nygren, H. Fridborg, K. Csoka, C. Sundstrom, M. de la Torre, J. Kristensen, J. Bergh, H. Hagberg, B. Glimelius, and J. Rastad Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients Int. J. Cancer 56 5 1994 715 720
22. A. Engert, A. Brown, and P. Thorpe Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins Leuk. Res. 15 11 1991 1079 1086
23. P. Brusa, F. Dosio, S. Coppo, D. Pacchioni, S. Arpicco, P. Crosasso, and L. Cattel In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody Farmaco 52 2 1997 71 81
24. R.J. Kreitman Toxin-labeled monoclonal antibodies Curr. Pharm. Biotechnol. 2 4 2001 313 325
25. P.O. Falnes, J. Wesche, and S. Olsnes Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment Biochemistry 40 14 2001 4349 4358
26. M.F. Melzig, G. Bader, and R. Loose Investigations of the mechanism of membrane activity of selected triterpenoid saponins Planta Med. 67 1 2001 43 48
27. D.J. Flavell, D.A. Boehm, A. Noss, S.L. Warnes, and S.U. Flavell Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin Br. J. Cancer 84 4 2001 571 578
28. D.J. Flavell, S.U. Flavell, D.A. Boehm, L. Emery, A. Noss, N.R. Ling, P.R. Richardson, D. Hardie, and D.H. Wright Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours Br. J. Cancer 72 6 1995 1373 1379
29. L. Pasqualucci, M. Wasik, B.A. Teicher, L. Flenghi, A. Bolognesi, F. Stirpe, L. Polito, B. Falini, and M.E. Kadin Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma Blood 85 8 1995 2139 2146
30. B.J. Morland, J. Barley, D. Boehm, S.U. Flavell, N. Ghaleb, J.A. Kohler, K. Okayama, B. Wilkins, and D.J. Flavell Effectiveness of HB2 (anti-CD7)-saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice Br. J. Cancer 69 2 1994 279 285
31. M. Colombatti, and F. Dosio Synthesis of monensin derivatives and their effect on the activity of ricin A-chain immunotoxins Methods Mol. Biol. 166 2001 55 70
32. B.S. Stein, K.G. Bensch, and H.H. Sussman Complete inhibition of transferrin recycling by monensin in K562 cells J. Biol. Chem. 259 23 1984 14762 14772
33. M. Mochizuki, Y.C. Yoo, K. Matsuzawa, K. Sato, I. Saiki, S. Tono-oka, K. Samukawa, and I. Azuma Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-Rb2, 20(R)- and 20(S)-ginsenoside-Rg3, of red ginseng Biol. Pharm. Bull. 18 9 1995 1197 1202
34. K. Sato, M. Mochizuki, I. Saiki, Y.C. Yoo, K. Samukawa, and I. Azuma Inhibition of tumor angiogenesis and metastasis by a saponin of Panax ginseng, ginsenoside-Rb2 Biol. Pharm. Bull. 17 5 1994 635 639